RBS2418 + durvalumab + tremelimumab

RBS2418 + durvalumab + tremelimumab is a **combination investigational cancer immunotherapy** comprising: - **RBS2418**, an oral small molecule inhibitor that specifically targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) to protect tumor microenvironment signaling molecules (cGAMP, ATP) and reduce immunosuppressive adenosine production, thereby activating antigen-presenting cells and promoting T-cell mediated anti-tumor immunity[3][6][9][10]. - **Durvalumab**, a monoclonal antibody acting as an immune checkpoint inhibitor by binding programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1, and thus restoring T cell function[1][2][4][8]. - **Tremelimumab**, another monoclonal antibody checkpoint inhibitor, targeting cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) to enhance T cell activity against cancer[1][2][4][5][8]. This combination has been explored for use in advanced, metastatic, and progressive solid tumors (including colorectal cancer) for patients who have failed standard treatments, aiming to stimulate more robust and synergistic anti-tumor immunity via multiple mechanisms[3][6][10].

Other names

RBS2418 + durvalumab + tremelimumab